Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Resistence at +100%, won't last long
I just saw premarket bounce up to $23.
I keep going back and reading these articles:
https://www.bbc.com/news/health-56352128
https://www.dailymail.co.uk/news/article-9346955/Blood-test-spot-Covid-patients-high-risk-dying.html
This study is going to have historical importance. Lenzilumab might end up being considered the turning point in Covid treatment. From when Covid went from a mostly untreatable condition to a condition that rarely leads to death.
https://immunology.sciencemag.org/content/6/57/eabg9873
One nice thing about the upcoming binary event is that it isn't very binary. HGEN is valued so low with a market cap of only $750 million that it is worth that amount if the drug fails. And fail probably isn't the right word to use because there is virtually zero chance that the trial won't at least produce good results. We know that GM-CSF is the key to preventing the cytokine storm. We know the eINDS patients did great. We know there were great results with the interim analysis. Good results is HGEN's floor. HGEN's ceiling is being the Covid treatment drug of choice.
That is CytoDyn's Scientic Advisory Board. They get paid by CytoDyn. Which one has said anything positive about CytoDyn publicly?
Dr John Bream has a Facebook page for a company that basically doesn't exist. He is "currently practicing in multiple Emergency Departments across North Carolina". Oh and then the page has the following disclaimer.
"Disclosures: Owns/has owned stock positions in companies dealing with COVID-related interests: PFE, MRNA, JNJ, CYDY, ATOS, NVAX, ENLV, REGN, DVAX, OCGN, ABT, MDT, BNGO, TMO".
So can anyone come up with one scientist not paid by CytoDyn who has spoken in favor of leronlimab?
You have previously said that Dr. Umang Khetarpal introduced you to leronlimab and that he is a brilliant doctor. Umang has been silent about leronlimab for months after being quite vocal previously. What does Umang think about trial results?
Doctors shouldn't be listened to at all. Scientists should be listened to: immunologists/epidemiologists/infectious disease specialists. Listening to doctors about experimental Covid drugs would be like listening to a waiter about your food order instead of the chef.
What is the connection between Scott Kelly, Chris Recknor, and Nick Agresti? They are all in Georgia. Did Scott Kelly go out and find some local doctors who could be swayed by the almighty dollar? Take a look at Nick Agresti's office. It looks like a mobile home. He does surgery in that building. On Health Grades, his patients complain about mold being everywhere in the building.
People do realize that it is very difficult to have a short position with CYDY? Schwab and Fidelity don't allow it for their regular customers. Only bigtime investors have the ability to short OTC stocks.
If anyone has time on their hands and wants a laugh, go back to 2016 in this thread. The same people are saying, "EUA just around the corner" or "revenue in months". It is 5 years later. No EUA. No revenue.
RLFTF's stock price has dropped over the last month in similar fashion to HGEN. But their 28 day topline results were released a month ago and results were poor. Their 60 day data is scheduled to be released on Monday and it it caused their stock to rise 10% on Friday. BRPA is a SPAC owns the rights to 50% of RLFTF's Covid drug for the US and 20% of worldwide rights. BRPA's stock price went up 36% on Friday. That same kind of price action could happen to HGEN on Monday to Wednesday.
Leronimab has a completely new indication:
https://twitter.com/adamfeuerstein/status/1375524115495391234/photo/1
I was thinking about Charlie Sheen's involvement with leronlimab. There is no evidence that he is only on leronlimab. He could be on other HIV treatments and that information is completely confidential. It has been reported in the news that he has had big financial problems because no one will hire him. Is it possible that he got paid to go on the Dr Oz show with Nader? I seriously doubt he would have any moral qualms about doing it. How much would it take, $500,000? His main source of income right now are videos of personal greetings that he does for $400 each. #winning